Repository logo
 
Publication

Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms

2021-04-20Journal article Open access
Simple item page
dc.contributor.authorBousquet, Jean
dc.contributor.authorSchröder-Bernhardi, Detlef
dc.contributor.authorBachert, Claus
dc.contributor.authorCanonica, G Walter
dc.contributor.authorCardona, Victoria
dc.contributor.authorCosta, Elísio
dc.contributor.authorCzarlewski, Wienczyslawa
dc.contributor.authorDevillier, Philippe
dc.contributor.authorFonseca, Joao A
dc.contributor.authorKlimek, Ludger
dc.contributor.authorKuna, Piotr
dc.contributor.authorLourenço, Olga
dc.contributor.authorMullol, Joaquim
dc.contributor.authorPfaar, Oliver
dc.contributor.authorPham-Thi, Nhân
dc.contributor.authorSamolinski, Boleslaw
dc.contributor.authorSaueressig, Julia
dc.contributor.authorScadding, Glenis K
dc.contributor.authorStroh, Ann-Kathrin
dc.contributor.authorScheire, Sophie
dc.contributor.authorVan Ganse, Eric
dc.contributor.authorZuberbier, Torsten
dc.date.accessioned2021-07-05T13:42:48Z
dc.date.available2021-07-05T13:42:48Z
dc.date.issued2021-04-20
dc.description.abstractBackground: The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. Methods: We conducted a pharmaco-epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS®- Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking-OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). Results: Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar. Discussion: There are major differences between countries in terms of rhinoconjunctivitis medication usage.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1111/cea.13884pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/11192
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectMIDASpt_PT
dc.subjectAllergic rhinitispt_PT
dc.subjectCostspt_PT
dc.subjectMedicationpt_PT
dc.subjectUnitspt_PT
dc.titleHeterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platformspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunologypt_PT
person.familyNameBousquet
person.familyNameBachert
person.familyNameCosta
person.familyNameFonseca
person.familyNameLourenço
person.familyNameMullol
person.familyNamePfaar
person.familyNameVAN GANSE
person.givenNameJean
person.givenNameClaus
person.givenNameElísio
person.givenNameJoão
person.givenNameOlga
person.givenNameJoaquim
person.givenNameOliver
person.givenNameEric
person.identifier851914
person.identifier.ciencia-id6D1F-B555-DD1B
person.identifier.ciencia-id8C15-586C-A437
person.identifier.ciencia-id6618-1C4C-D1B7
person.identifier.orcid0000-0002-4061-4766
person.identifier.orcid0000-0003-4742-1665
person.identifier.orcid0000-0002-3987-7278
person.identifier.orcid0000-0002-0887-8796
person.identifier.orcid0000-0002-8401-5976
person.identifier.orcid0000-0003-3463-5007
person.identifier.orcid0000-0003-4374-9639
person.identifier.orcid0000-0002-7463-9187
person.identifier.ridB-7562-2008
person.identifier.ridD-5876-2015
person.identifier.scopus-author-id45661083200
person.identifier.scopus-author-id9744229500
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication50a12f1e-371a-4efe-bf31-df198fffeaca
relation.isAuthorOfPublication7cfb45bf-9990-4ef6-a0d8-3964c9e317ad
relation.isAuthorOfPublication44bae1b8-f0fe-4cc7-8359-f4ef0513a5b8
relation.isAuthorOfPublication8552c1f0-f775-46ba-9a9b-f66a87d9dc2f
relation.isAuthorOfPublicationc890c74a-abc1-4910-aa70-f0da7b4ad902
relation.isAuthorOfPublication5a3f988b-b188-402c-be9b-16eb14129a2b
relation.isAuthorOfPublication71a7563e-c14b-4068-900b-2dfc14fe6975
relation.isAuthorOfPublication362d3114-1cfa-461f-9289-0a8707a9e6e4
relation.isAuthorOfPublication.latestForDiscovery5a3f988b-b188-402c-be9b-16eb14129a2b

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2021_Bousquet J_Midas.pdf
Size:
1.24 MB
Format:
Adobe Portable Document Format
Download

Collections

ICI - CICS | Documentos por Auto-Depósito
FCS - DCM | Documentos por Auto-Depósito